Form 4: Director Christopher Payne Receives HIMS Equity Grant

Director Christopher D. Payne was granted 647 restricted stock units in lieu of cash compensation for Q1 2026.

Summary

• Director Christopher D. Payne received 647 Restricted Stock Units (RSUs) from Hims & Hers Health, Inc.
• The grant was issued in lieu of $14,875 in cash director retainer and committee fees for the first quarter of 2026.
• The grant price was calculated at $22.98 per share.
• The RSUs are scheduled to vest in full on the next quarterly vesting date, June 15, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that has no material impact on the company's financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Preservation of company cash by electing to receive stock in lieu of cash fees.

Negatives

• None identified.

Risks

• Market price volatility of HIMS Class A Common Stock could impact the future value of the equity grant.

Future Outlook

The RSUs will vest in full on the company's next quarterly vesting date, June 15, 2026.

Industry Context

StockSavvy.ai notes that it is standard corporate governance practice for directors to receive equity in lieu of cash to demonstrate long-term commitment to the company's performance.

Comparison to Industry Standards

• The practice of issuing RSUs to directors in lieu of cash is a common industry standard for growth-stage companies to conserve cash flow.
• The compensation structure aligns with typical board remuneration policies for mid-cap healthcare technology firms.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation adjustment.

Next Steps

• Vesting of 647 RSUs on June 15, 2026.

Key Dates

Keywords

HIMS, Hims & Hers Health, Director Compensation, Restricted Stock Units, Insider Transaction, Equity Grant